Searched for
GLICLAZIDE
16 fixed-dose combination drugs banned in India: Check full list hereFixed dose combination banned full list: India has banned 16 fixed-dose combination drugs, including certain antibiotics and antispasmodics...- India bans 16 fixed-dose drug combinations over safety concernsIn a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...
- NPPA fixes retail prices of 23 drug formulationsSimilarly, the retail price of one tablet of Telmisartan, Chlorthalidone & Cilnidipine tablets at Rs 13.17. The retail price of one tablet ...
- Asahi Songwon Colors zooms 4% after buying 78% stake in Atlas Life SciencesAsahi Songwon’s share price climbed to a high of Rs 346.45 as against Rs 332.70 at previous close on the BSE. The stock succumbed to profit...
- Panacea Biotec sells domestic formulation assets to Mankind Pharma for Rs 1,908 crorePanacea said it expects to complete the transaction by the end of this year.
- NPPA caps prices of 43 drug formulation packs"The prices have been fixed / revised in respect of 43 formulation packs, both ceiling and retail price packs, under DPCO, 2013," NPPA said.
- NPPA order may not impact much, seeking legal advice: Dr Reddy'sDrug pricing regulator NPPA has fixed the price of 108 non-scheduled formulation packs of 50 anti-diabetes and cardiac medicines.
- Sanofi India shares tank over 10% on price control orderSanofi India's stock tanked 10.22 per cent to settle at Rs 2,900. In intra-day trade, the scrip plunged 10.99 per cent to Rs 2,875.
- Prices of 108 diabetes, cardiac formulations fixed: NPPAThe drugs that will become cheaper would include atorvastatin, gliclazide, glimepiride, heparin and metolazone among others.
- Major diabetes, cardiac drugs to become up to 35 per cent cheaperPrices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35 per cent over the next few weeks.
- Bal Pharma to raise $20 mn for expansionBangalore-based pharma company Bal Pharma is planning to raise $20 million for capacity expansion and asset acquisition.
- Ethypharm signs out-licensing deal with GlobalpharmaPharma major Ethypharm India, has signed a major out-licensing deal for five new products in different therapeutic segments, with UAE-based...
Load More
